SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is drawing intense community focus after reports that it plans to monetize excess AI compute capacity through a new cloud offering, a strategic shift that has sparked heated debate over whether it signals genuine revenue diversification or underlying desperation regarding capital expenditure. Traders are actively clashing over the long-term impact on the AI infrastructure ecosystem, as the stock faces volatile price action driven by conflicting narratives about compute scarcity versus potential overcapacity.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing intense selling pressure as investors react to a significant executive compensation package that lacks immediate performance milestones, coupled with broader market volatility in the AI infrastructure sector. The community is deeply divided between long-term bulls who view the current price drop as an aggressive accumulation opportunity and vocal critics who are questioning management's capital allocation and execution speed.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility and aggressive profit-taking, fueling a heated debate among investors about whether this marks a fundamental trend reversal or a healthy correction within the broader semiconductor cycle. While the community remains polarized, many are closely monitoring key support levels to determine if the stock will stabilize or face further downside following its recent parabolic run.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing intense volatility as investors weigh the company's aggressive pivot toward AI infrastructure against the reality of legacy revenue declines and heavy debt. While the community is actively debating the durability of its fiber footprint and the potential for a transformative 'J-curve' revenue inflection, the stock's price action is being heavily driven by mechanical forces like index rebalancing and short-term speculative trading.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as investors debate its pivot toward AI infrastructure and high-performance computing, with sentiment heavily divided by management's strategic communication and dilution concerns. The community is actively discussing the stock's volatility relative to Bitcoin's price movements and the potential for a long-term turnaround based on pending data center tenant deals.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently a focal point for investors as the community debates the significance of its recent research agreement with Honda alongside the potential for upcoming manufacturing milestones related to its 'Eagle Line' production. While some market participants are actively adding positions in anticipation of future commercial breakthroughs, others remain vocal about their frustration regarding the stock's stagnant price action and limited revenue generation.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is experiencing significant volatility and trading momentum following a 13G filing revealing that Michael Platts BlueCrest Capital Management has taken a 5.6% stake. The community is actively debating whether this institutional interest signals a sustainable growth phase for the company's humanoid robotics ambitions or if the move is merely a short-term catalyst in an otherwise speculative SPAC environment.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following positive interim Phase 1/2a results for its ARO-INHBE and ARO-ALK7 obesity programs, which demonstrated significant potential as combination therapies to enhance weight and visceral fat loss. The community is actively discussing the clinical data's impact on Arrowhead's long-term valuation and pipeline competitiveness, with many investors debating the company's potential as a major acquisition target.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending following a surprise announcement of a $350 million convertible senior notes offering, an unexpected move that has sparked investor frustration given the company's existing $2 billion cash balance. While the community is actively debating whether this signals a strategic acquisition, an attempt to bolster the pipeline, or poor capital discipline, many shareholders are expressing deep dissatisfaction with management, citing the stock's long-term underperformance and the lack of clarity regarding the dilution event.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is currently surging as investors re-rate the company from a traditional Bitcoin miner into a significant artificial intelligence infrastructure play. The recent announcement of a major multi-year data center lease has triggered intense community interest and a significant price rally, with many discussing the stock's transition as a catalyst for institutional re-valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns

Equity

H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target on Thursday.


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 1, 2026 NEW YORK, July 1, 2026...

Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug

Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing durable safety profile and clinical improvements compared to natural history data.read more...

Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know

Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the accelerated approval of nomlabofusp for Friedreich’s ataxia.

Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC

AIGH Capital Management LLC lifted its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 100.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the compa...

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have...

Larimar Therapeutics (LRMR) to Release Earnings on Wednesday

Larimar Therapeutics (NASDAQ:LRMR) will be releasing its Q1 2026 earnings before the market opens on Wednesday, April 29. (View Earnings Report at...

Q1 Earnings Estimate for LRMR Issued By Lifesci Capital

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Lifesci Capital issued their Q1 2026 EPS estimates for Larimar Therapeutics in a report issued on Wednesday, April 1st...

Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have received an average recommendation of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat.com...

Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday

Larimar Therapeutics (NASDAQ:LRMR) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-larimar-therapeutics-inc-stock...

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.38	--	--	N/A
Q1 '26	-$0.53	-$0.31	42.01%	BEAT
Q4 '25	-$0.48	-$0.73	-53.60%	MISSED
Q3 '25	-$0.40	-$0.61	-51.10%	MISSED
Q2 '25	-$0.48	-$0.41	14.63%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

LRMRLarimar Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest LRMR News